AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03795064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothermal ablation
Description: Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
Study NCT00434148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study NCT01005407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV and/or Placebo
Description: Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
Study NCT01005407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections on Week 0, Week 4 and Week 24
Study NCT06299631 — intervention group
Intervention type: PROCEDURE
Intervention: Ileocolic resection
Description: Ileocolic resection by open or laparoscopic approach
Study NCT03739684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
Study NCT03739684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Description: PET/CT imaging will be acquired 1-2 hours post-PyL injection
Study NCT01832545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Study NCT01832545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: Control Group
Study NCT01139892 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical management
Study NCT01139892 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular management
Study NCT00828516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Description: Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
Study NCT03888092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z650
Description: receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study NCT02532023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acid
Description: omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
Study NCT02532023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
Study NCT02532023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega 3 fatty acid placebo
Description: omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
Study NCT02532023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: curcumin placebo
Description: curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
Study NCT00927979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mLRopivacaine 1%
Description: Intraperitoneal nebulization of 10 mL Ropivacaine 1%
Study NCT00927979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Intraperitoneal nebulization of 10 mL water for injection
Study NCT00927979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mL Ropivacaine 1%
Description: Intraperitoneal nebulization of 10 mL Ropivacaine 1%
Study NCT01552629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Study NCT01552629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01552629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Study NCT00990093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test intermittent catheter
Description: CH 12 hydrophilic coated catheter
Study NCT00990093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization
Description: CH 12 hydrophilic catheter
Study NCT01093365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: * 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days
Study NCT03125915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training video
Description: This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
Study NCT03125915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: substance use module
Description: This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
Study NCT01854554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
Study NCT03881462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary nerve block for artificial deltoid muscle palsy
Description: Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid.
Study NCT01658683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Facilitator Intervention
Description: The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
Study NCT03736200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming group
Description: Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
Study NCT03736200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 4-week-long.
Study NCT03736200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming group 2/day
Description: Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
Study NCT04718246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dental Implants Placed In hyperlipidemia patients
Description: A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks
Study NCT04020731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
Study NCT03297879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide or metformin hydrochloride
Description: Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
Study NCT03297879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide or metformin hydrochloride
Description: Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
Study NCT03868904 — intervention group
Intervention type: DEVICE
Intervention: OCS Lung System
Description: No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
Study NCT03125915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples HIV Testing and Counseling
Description: CHTC delivered as per the CDC protocol.
Study NCT00934193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
Study NCT00934193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
Study NCT03751904 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AcoustiCare
Description: Electronic stethoscope
Study NCT04410432 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study
Study NCT00572572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
Study NCT00572572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Intrathecal/ Intravenous/ Oral
Study NCT00958919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: 10 mg naloxone in 25 ml total volume
Study NCT00958919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 25 ml
Study NCT01573702 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: 21 Gy daily for 5 days
Study NCT01573702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150mg once daily
Study NCT03142074 — intervention group
Intervention type: OTHER
Intervention: Biomechanical and microstructural analysis of ATAA
Description: Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
Study NCT03142074 — intervention group
Intervention type: RADIATION
Intervention: ECG-gated CT
Description: Image analysis of ECG-gated CT.
Study NCT02390804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-port laparoscopic hysterectomy(single port trochar)
Description: perform laparoscopic hysterectomy via single-port access
Study NCT02390804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multi-port laparoscopic hysterectomy(multi port trochar)
Description: perform laparoscopic hysterectomy via multi-port access
Study NCT03883672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality and transactional factors
Description: 1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)
Study NCT01231711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vets Prevail
Description: The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills.
Study NCT03936244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Description: Randomized allocation to M-TURP or PK-TURP
Study NCT03936244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Description: Randomized allocation to M-TURP or PK-TURP
Study NCT01973790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-338
Description: 100mg TID
Study NCT00975234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-lesion injection of autologous skeletal myoblasts
Description: Intra-lesion injection
Study NCT00975234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Revascularisation
Description: Revascularisation surgery
Study NCT00975234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularisation
Description: Revascularisation surgery
Study NCT03790982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AD-35 60mg /AD-35 30mg
Description: Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
Study NCT03790982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AD-35 60mg /AD-35 60mg
Description: Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
Study NCT03790982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-35 30 mg + Placebo of AD-35 30 mg
Description: AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
Study NCT03790982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-35 60 mg
Description: AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
Study NCT01114646 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cemented Hip Hemiarthroplasty
Description: The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
Study NCT01114646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerSys Beaded FullCoat, Zimmer
Description: The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
Study NCT04735133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pNBYT
Description: pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
Study NCT01513304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Study NCT03060941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity education
Description: Participants will be given educational materials on how to increase physical activity levels.
Study NCT03125915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couples HIV Testing and Counseling
Description: CHTC delivered as per the CDC protocol.
Study NCT03147521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care bundle
Description: Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
Study NCT03147521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care bundle
Description: Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
Study NCT01770639 — intervention group
Intervention type: PROCEDURE
Intervention: MFB
Description: Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
Study NCT00488839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 20 mg
Description: IPX056 Extended Release capsule containing 20 mg baclofen
Study NCT00488839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 40 mg
Description: IPX056 Extended Release capsule containing 40 mg baclofen
Study NCT03060941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility access
Description: Participants will receive at 6 month membership to a local fitness facility.
Study NCT00488839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Encapsulated Baclofen 20 mg
Description: Baclofen 20mg tablet was encapsulated for blinding.
Study NCT03060941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise sessions
Description: Participants will attend weekly supervised exercise sessions with an exercise interventionist.
Study NCT03060941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring (Fitbit)
Description: Participants will be given a Fitbit to monitor their physical activity levels.
Study NCT03060941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active living counseling
Description: Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
Study NCT02013765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Intravenous
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Intravenous